Literature DB >> 14754789

Do clozapine and risperidone affect social competence and problem solving?

Alan S Bellack1, Nina R Schooler, Stephen R Marder, John M Kane, Clayton H Brown, Ye Yang.   

Abstract

OBJECTIVE: The purpose of this investigation was to evaluate the effects of clozapine and risperidone on social skill and problem solving in patients with schizophrenia.
METHOD: The Wisconsin Card Sorting Test and the Maryland Assessment of Social Competence were administered at baseline, week 17, and week 29 of a multisite clinical trial.
RESULTS: Despite evidence of clinical improvement with both medications, there was virtually no medication effect on either social competence or problem solving.
CONCLUSIONS: These findings underscore the circumscribed nature of symptomatic improvement in the broader spectrum of clinical outcomes and suggest that new-generation medications may not be expected to produce substantial changes in social role functioning or social problem-solving capacity in the community. The generalizability of the findings should be viewed cautiously because of the low power of this trial, and replication is warranted.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 14754789     DOI: 10.1176/appi.ajp.161.2.364

Source DB:  PubMed          Journal:  Am J Psychiatry        ISSN: 0002-953X            Impact factor:   18.112


  17 in total

1.  Quality of life and social functioning of former long-stay psychiatric patients transferred into the community: a 10 year follow up study.

Authors:  S J McInerney; S Finnerty; E Walsh; L Spelman; N E Edgar; B Hallahan; C McDonald
Journal:  Soc Psychiatry Psychiatr Epidemiol       Date:  2018-04-28       Impact factor: 4.328

Review 2.  Risperidone versus other atypical antipsychotics for schizophrenia.

Authors:  Katja Komossa; Christine Rummel-Kluge; Sandra Schwarz; Franziska Schmid; Heike Hunger; Werner Kissling; Stefan Leucht
Journal:  Cochrane Database Syst Rev       Date:  2011-01-19

Review 3.  Clozapine versus other atypical antipsychotics for schizophrenia.

Authors:  Claudia Asenjo Lobos; Katja Komossa; Christine Rummel-Kluge; Heike Hunger; Franziska Schmid; Sandra Schwarz; Stefan Leucht
Journal:  Cochrane Database Syst Rev       Date:  2010-11-10

4.  Improved cognitive function in schizophrenia after one year of cognitive training and vocational services.

Authors:  Tamasine C Greig; Wayne Zito; Bruce E Wexler; Joanna Fiszdon; Morris D Bell
Journal:  Schizophr Res       Date:  2007-07-31       Impact factor: 4.939

Review 5.  Clozapine versus typical neuroleptic medication for schizophrenia.

Authors:  Adib Essali; Nahla Al-Haj Haasan; Chunbo Li; John Rathbone
Journal:  Cochrane Database Syst Rev       Date:  2009-01-21

6.  Prenatal stress generates deficits in rat social behavior: Reversal by oxytocin.

Authors:  Paul R Lee; Dana L Brady; Robert A Shapiro; Daniel M Dorsa; James I Koenig
Journal:  Brain Res       Date:  2007-04-22       Impact factor: 3.252

7.  Can Social Functioning in Schizophrenia Be Improved through Targeted Social Cognitive Intervention?

Authors:  David L Roberts; Dawn I Velligan
Journal:  Rehabil Res Pract       Date:  2012-06-13

8.  Genetic underpinnings of sociability in the general population.

Authors:  Janita Bralten; Nina R Mota; Barbara Franke; Geert Poelmans; Cornelius J H M Klemann; Ward De Witte; Emma Laing; David A Collier; Hilde de Kluiver; Stephanie E E C Bauduin; Celso Arango; Jose L Ayuso-Mateos; Chiara Fabbri; Martien J Kas; Nic van der Wee; Brenda W J H Penninx; Alessandro Serretti
Journal:  Neuropsychopharmacology       Date:  2021-05-30       Impact factor: 7.853

Review 9.  Can antipsychotics improve social cognition in patients with schizophrenia?

Authors:  Katarzyna Kucharska-Pietura; Ann Mortimer
Journal:  CNS Drugs       Date:  2013-05       Impact factor: 5.749

10.  Response to: A Commentary on "Antipsychotic-Induced Parkinsonism is Associated with Working Memory Deficits in Schizophrenia-Spectrum Disorders".

Authors:  Stéphane Potvin; Andràs Tikàsz
Journal:  Front Behav Neurosci       Date:  2015-08-12       Impact factor: 3.558

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.